Inositols in Polycystic Ovary Syndrome: An Overview on the Advances

Area of Science:

• Endocrinology
• Reproductive Biology
• Metabolic Disorders

Background:

• Myo-inositol (MI) and d-chiro-inositol (DCI) are inositol isomers with distinct physiological roles.
• Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder often associated with insulin resistance.

Purpose of the Study:

• To review the physiological functions of MI and DCI.
• To define an optimal therapeutic strategy for PCOS using MI and DCI.
• To explore methods for improving inositol bioavailability.

Main Methods:

• Literature review of studies on inositol physiology and PCOS treatment.
• Analysis of the roles of MI as a second messenger for follicle-stimulating hormone (FSH).
• Analysis of the role of DCI as an aromatase inhibitor.

Main Results:

• MI acts as an FSH second messenger in the human ovary, while DCI inhibits aromatase.
• A combined administration of MI and DCI at a 40:1 ratio is proposed as an effective PCOS treatment.
• MI potentiates the fertility effects of metformin and clomiphene in PCOS patients.
• Alpha-lactalbumin may enhance intestinal absorption of inositols.

Conclusions:

• The distinct physiological activities of MI and DCI inform their use in PCOS management.
• Specific dosages and ratios, like 40:1 MI:DCI, are crucial for effective PCOS treatment.
• Improving inositol absorption, potentially with alpha-lactalbumin, is important for treatment success.